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Abstract Whole exome sequencing (WES) is a recently
developed technique in genetics research that attempts to
identify causative mutations in complex, undiagnosed ge-
netic conditions. Causative mutations are usually identified
after filtering the hundreds of variants on WES from an
individual’s DNA selected by the phenotype. We investi-
gated a patient with a slowly progressive chronic axonal
distal motor neuropathy and extrapyramidal syndrome us-
ing WES, in whom common genetic mutations had been
excluded. Variant filtering identified potentially deleterious
mutations in three known disease genes: DCTN1, KIF5A
and NEFH, which have been all associated with similar
clinical presentations of amyotrophic lateral sclerosis,
Parkinsonism and/or hereditary spastic paraplegia. Pre-
dicting the functional effect of the mutations were analysed
in parallel with detailed clinical investigations. This case
highlights the difficulties and pitfalls of applying WES in
patients with complex neurological diseases and serves as
an instructive tale.
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Abbreviations
ALS Amyotrophic lateral sclerosis
HSP Hereditary spastic paraplegia
CMT Charcot–Marie–Tooth disease
Introduction
Whole exome sequencing (WES) is an increasingly
available second-generation sequencing technique that
identifies variants in the coding regions of the human
genome [1]. In the field of neurology, it has helped pa-
tients by elucidating the cause of their often long-standing
symptoms, and many previously undiagnosed patients
with a range of neurological syndromes which can now be
given the name of the causative gene and counselled
appropriately. For researchers, WES has led to the rapid
rise in the discovery of novel mutations in both known
and novel disease genes, further unravelling the cellular
function and relationships of various genes with human
disease. However, one of the many limitations of WES is
in its application to single patients with late-onset disease.
WES of one individual’s DNA can identify up to 20,000
variants [1]. Even in patients with a characteristic clinical
phenotype choosing the causative mutation remain a
challenge if DNA from other affected or healthy relatives
is not available to determine which variant segregates
with the phenotype [2].
Here we describe a case wherein, we used WES to guide
diagnosis in a patient with complex neurodegenerative
disease.
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Methods
We assessed the patient’s clinical history, examination and
serological, neurophysiological, radiological and histo-
logical investigations. Exome sequencing was carried out
using genomic blood DNA by Illumina TruseqTM 62 Mb
exome capture. We used our in-house bioinformatics
pipeline to align data to the reference human genome
(UCSC hg19), remove duplicate sequence reads (Picard
v1.85) and variant detection (Varscan v2.29, Dindel
v1.0110). Results were filtered for variants with a minor
allele frequency less than 0.01 in several databases:
dbSNP135, 1000 genomes (February 2012 data release),
the National Heart, Lung and Blood Institute (NHLBI,
NIH, Bethesda, MD) Exome Sequencing Project (ESP)
6500 exomes, and 238 unrelated in-house controls. Rare
homozygous and compound heterozygous variants were
defined, and protein altering and/or putative ‘disease-
causing’ mutations, along with their functional annotation,
were identified using ANNOVAR. Further filtering has
been performed by gene ontology (GO) terms associated
with neuronal function, and Online Mendelian Inheritance
in Man (OMIM) disease descriptions related to neuropathy,
ataxia or extrapyramidal disorders (i.e., the patient’s clin-
ical phenotype). We carried out PCR (IMMOLASETM
DNA Polymerase, Bioline UK) and Sanger sequencing
(BigDye Terminator v3.1) of variants predicted to be
deleterious by five online prediction tools (MutationTaster,
SIFT, Polyphen2, A-GVGD, and LRT).
Results
Case report
A 74-year-old left-handed man originally presented at the
age of 45 with right-sided back pain and sciatica as well as
bilateral grip weakness. His gait had also changed but he was
able to walk and play sports. Past medical history included
poliomyelitis at the age of ten, during the 1950s epidemic.
Both of his parents died at age 88 and 72, and had no
neuromuscular symptoms. He has one son and four
daughters (28–36 years of age), and one daughter was re-
cently diagnosed with multiple sclerosis. He has a 71-year-
old healthy brother who was not available for testing.
At age 45, examination revealed wasting and weakness
of the right sternocleidomastoid muscle, bilateral wasting
of thenar and intrinsic hand muscles (Fig. 1a). In particular,
the abductor pollicis brevis was weak bilaterally. There
was distal lower limb weakness with foot drop but no pes
cavus. Tone and reflexes were normal.
He was seen again at the age of 64 with worsening
torticollis. He had jerky ocular pursuit movements and
bilateral wasting of the tongue. His previous weakness had
persisted with additional weakness in the shoulders. He had
developed pes cavus bilaterally (Fig. 1a), brisk upper limb
and knee reflexes with absent ankle reflexes bilaterally. He
progressed to develop dysmetria and dysdiadochokinesis
but no dysarthria.
More recent examination at 74 years revealed progres-
sion of the complex movement disorder with facial dys-
tonia, head tremor, distal amyotrophy, ataxia and some
rigidity at the wrists. He had a wide-based steppage gait
with reduced arm swing.
Investigations
Basic haematological and biochemical investigations were
normal except for gamma-glutamyl transferase (83 units/L,
normal \70), creatine kinase (193 and 215 U/L, normal
10–190), random glucose (8.3 mmol/L), cholesterol
(7.9 mmol/L, normal\5.2) and triglycerides (6.1 mmol/L,
normal fasting level \1.8). Thyroid function tests, auto-
antibodies, Vitamin E, 24-h urinary copper, alpha-feto-
protein, lysosomal enzymes, hexosaminidase A were all
within normal limits.
Brain MRI revealed marked cerebellar atrophy and mild
cortical atrophy without signal change (Fig. 1b). Cervical
MRI showed mild spondylotic changes at C5/6 and C6/7.
DatScan showed no abnormalities in dopamine metabo-
lism. Nerve conduction studies demonstrated preserved
sensory nerve action potentials, sensory and motor con-
duction velocities but symmetrically diminished compound
motor potentials in all four limbs, suggesting that the
syndrome could not be attributed to previous poliomyelitis.
Electromyography revealed chronic neurogenic changes,
suggesting spinal muscular atrophy or distal spinal mus-
cular atrophy. With electromyography, unstable polyphasic
units were observed with reduced interference and ampli-
tudes up to 10 mV, confirming a chronic progressive an-
terior horn cell disease. Muscle biopsy showed only
neurogenic changes.
Genetic analysis
Genetic tests performed before WES excluded Hunting-
ton’s disease (IT15), spinal muscular atrophy (SMN1),
spinal bulbar muscular atrophy (AR), primary torsion
dystonia (DYT1), and the common forms of spastic para-
plegias (SPG4, REEP1, ATL1, SPG7). No mtDNA dele-
tions were detected in his muscle DNA. Rare, potentially
disease-causing variants found in filtered WES data are
listed in Tables 1 and 2; we could confirm all variants in
heterozygous state in the patient’s DNA by Sanger se-
quencing. No further mutations were detected in any of the
known disease genes involved in inherited movement
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Fig. 1 a Photographs of the patient demonstrating a partially treated torticollis, a broad-based stance, distal upper and lower limb atrophy as well
as bilateral pes cavus. b MRI of the patient’s brain demonstrating cerebellar atrophy
Table 1 Predicted deleterious variants filtered from whole exome sequencing data
Gene Position Variant Bioinformatic score Disease association
DCTN1 Chr2:g.74588640 C NM_004082.4: c.3823 C[T, p.Arg1275Cys 5 ALS, Perry syndrome
KIF5A Chr12:g.57965854 C NM_004984.2: c.1373 C[T, p.Ser458Phe 3.5 HSP, CMT
NEFH Chr22:g.29885580_2988 603 NM_021076.3: c.1965 1988del, p.Glu658_Lys665del N/A ALS
Scores were calculated from the output of five mutation deleteriousness prediction programmes: SIFT (score 1 for prediction of ‘Deleterious’, 0
for others), LRT (score 1 for prediction of ‘Deleterious’), Polyphen2 (score 1 for ‘probably damaging’ prediction, 0.5 for ‘possibly damaging’
prediction, 0 for ‘benign’), Align-GVGD (score 1 for predictions C55 or C66, score 0 for other predictions) and MutationTaster (score 1 for
‘disease-causing’ prediction, 0 for ‘polymorphism). Predictions were not available for the deletion in the NEFH gene
Table 2 Coverage and depth statistics of exome sequencing for the patient
Mean target
base
coverage
Number of
bases covered
20-fold
% Bases
covered
20-fold
Number of
bases covered
tenfold
% Bases
covered
tenfold
Number of
bases covered
fivefold
% Bases
covered
fivefold
Number of
bases covered
onefold
% Bases
covered
onefold
88.23 29129128 91.21 30151406 94.41 30585401 95.77 31131999 97.49
Coverage calculated for Consensus Coding Sequence (CCDS) bases (31,935,069 bp)
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disorders, neuropathies or spastic paraplegias and no fur-
ther family members were available for genetic analysis.
Discussion
We have found novel, potentially pathogenic mutations in
the patient in multiple genes (DCTN1, KIF5A, NEFH) as-
sociated with various neurological syndromes. Based on
previous reports, heterozygous mutations in all three genes
can be associated with similar clinical presentation ob-
served in our case. In further support of the pathogenic
role, the selected variants have not been reported previ-
ously at all (KIF5A) or are extremely rare (one single
heterozygous DCTN1 and NEFH variant in 65,000 exomes
(http://exac.broadinstitute.org/).
DCTN1 mutations have been associated with a familial
form of ALS (p.Gly59Ser) [3], familial progressive
supranuclear palsy [4], Perry syndrome (p.Gly71Ala/Glu/
Arg, p.Thr72Pro, and p.Gln74Pro) which is characterized
by central hypoventilation and parkinsonism [5]. Our pa-
tient exhibited a distal motor neuropathy with ataxia and an
extrapyramidal syndrome of tremor and focal dystonia—an
inexact fit with the previously described phenotypes of
DCTN1. However, the involvement of the spinal motor
neurones in combination with a movement disorder re-
sembles DCTN1-related disease and our patient may rep-
resent a new phenotype associated with DCTN1 mutation.
DCTN1 codes for the p150glued subunit of the dynactin
complex, which together with dynein is responsible for ret-
rograde transport of vesicle cargo in axons [6]. The C-ter-
minal region of p150glued has been shown in N. crassa to be
responsible for the interaction of the dynactin complex with
membranous cargo [7]. However, previous work in HeLA
and COS7 cells could not confirm that mutations in the
C-terminal region of DCTN1 (Arg1101Lys and Thr1249Ile)
are functionally pathogenic [8]. Our patient’s DCTN1 mu-
tation is located to this region; nevertheless, this variant has
not been reported previously and no functional data are
available on it to date. However, functional in vivo imaging
studies in patients possessing the variants associated with
Perry syndrome, have demonstrated a reduced uptake of
FDOPA, a marker of dopamine synthesis and storage [9].
Mutations in KIF5A are associated with spastic para-
plegia (SPG10), and can also cause peripheral neuropathy,
parkinsonism, retinitis pigmentosa and behavioural prob-
lems [10, 11]. Therefore, the pyramidal signs in our patient
may also represent a KIF5A-related disease. KIF5A codes
for the kinesin heavy chain which is responsible for an-
terograde transport of cargo (thought to be neurofilaments)
towards the synapse [12]. The KIF5A mutation in our pa-
tient occurs in the neck region that links two domains in the
protein [10]. To our knowledge, only one mutation (p.
Ala361Val) has previously been reported in the neck re-
gion in spastic paraplegia [13]; however, its pathogenic
role has not been confirmed in functional studies [14].
WES also detected a heterozygous 24-base pair deletion
in the neurofilament heavy chain (NEFH) gene in our pa-
tient. Such deletions of a lysine-serine-proline unit, that
shorten the repetitive tail region of the NEFH protein, have
been associated with an increased risk of developing ALS
[15], but no highly penetrant causative alleles have been
described in this gene.
Another intriguing point is the poliomyelitis in our pa-
tient’s previous history. Whether the childhood neuropathy
was indeed poliomyelitis, and coupled with a potentially
deleterious mutation contributed to the development of a
slowly progressive predominantly distal motor neuropathy,
or the childhood onset polio-like neuropathy represents the
first manifestation of a genetic condition remains unclear.
This case illustrates the problems that can be encoun-
tered in using next generation sequencing to guide the di-
agnosis of sporadic cases. Despite having confirmed
potentially disease-causing mutations in DCTN1 and
KIF5A, as well as a genetic predisposing variant in NEFH,
we cannot surely prove that they are the cause for the
patient’s phenotype without an informative family history,
which is often not available in late-onset disease. The ab-
sence of clinical signs and symptoms in younger family
members may simply reflect a later disease onset or low
penetrance of the mutation rather than its non-pathogeni-
city. Moreover, we cannot exclude the possibility that more
than one of the variants are relevant, and the different
aspects of the patient’s condition potentially may have
independent causes.
The case also highlights the importance of clinical his-
tory and examination in filtering through the enormous
number of possible diagnoses generated by the results of
next generation sequencing, and the need for functional
studies at a molecular level to identify which mutation
contributes to the cellular dysfunction. The overlapping
phenotypes of genetic forms of ALS, HSP and dystonia
highlight the importance of an unbiased testing approach,
but also illustrate the difficulties of confirming the genetic
diagnosis and functional tests provided evidence for the
pathogenicity of these mutations are still lacking.
In conclusion, we present a patient with a complex
neurological phenotype including predominantly distal
motor neuropathy, extrapyramidal and cerebellar signs for
whom we have identified a number of potentially patho-
genic candidate mutations.
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